CLOVER BIO-B (02197) Announces Monthly Return for February 2026

Bulletin Express03-05

Clover Biopharmaceuticals, Ltd. published its monthly return for the month ended 28 February 2026. The authorized share capital remained at 2.00 billion ordinary shares with a par value of US$0.0001 each, totaling US$0.20 million. The total number of issued shares stayed at 1.30 billion, with no movement in share issuance or repurchases.

The public float requirement of 25% was confirmed to be satisfied. The company reported no new share issuances through its Pre-IPO or Post-IPO Share Option Plans. Outstanding share options remained at 1.51 million under the Pre-IPO plan and 32.66 million under the Post-IPO plan, both unchanged from the previous month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172104516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172104516","market":"hk","top_or_hot":-1,"title":"CLOVER BIO-B (02197) Announces Monthly Return for February 2026","media":"Bulletin Express","content":"<p>Clover Biopharmaceuticals, Ltd. published its monthly return for the month ended 28 February 2026. The authorized share capital remained at 2.00 billion ordinary shares with a par value of US$0.0001 each, totaling US$0.20 million. The total number of issued shares stayed at 1.30 billion, with no movement in share issuance or repurchases.</p>\n<p>The public float requirement of 25% was confirmed to be satisfied. The company reported no new share issuances through its Pre-IPO or Post-IPO Share Option Plans. Outstanding share options remained at 1.51 million under the Pre-IPO plan and 32.66 million under the Post-IPO plan, both unchanged from the previous month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOVER BIO-B (02197) Announces Monthly Return for February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOVER BIO-B (02197) Announces Monthly Return for February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 17:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals, Ltd. published its monthly return for the month ended 28 February 2026. The authorized share capital remained at 2.00 billion ordinary shares with a par value of US$0.0001 each, totaling US$0.20 million. The total number of issued shares stayed at 1.30 billion, with no movement in share issuance or repurchases.</p>\n<p>The public float requirement of 25% was confirmed to be satisfied. The company reported no new share issuances through its Pre-IPO or Post-IPO Share Option Plans. Outstanding share options remained at 1.51 million under the Pre-IPO plan and 32.66 million under the Post-IPO plan, both unchanged from the previous month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1172104516","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172104516","pubTimestamp":1772703324,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Clover Biopharmaceuticals, Ltd. published its monthly return for the month ended 28 February 2026. The authorized share capital remained at 2.00 billion ordinary shares with a par value of US$0.0001...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"三叶草生物-B(02197)公布2026年2月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals, Ltd. published its monthly return for the month ended 28 February 2026. The authorized share capital remained at 2.00 billion ordinary shares with a par value of US$0.0001 each, totaling US$0.20 million. The total number of issued shares stayed at 1.30 billion, with no movement in share issuance or repurchases.\nThe public float requirement of 25% was confirmed to be satisfied. The company reported no new share issuances through its Pre-IPO or Post-IPO Share Option Plans. Outstanding share options remained at 1.51 million under the Pre-IPO plan and 32.66 million under the Post-IPO plan, both unchanged from the previous month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172104516","isCrawlerRequest":true}